Spring Bank Pharmaceuticals and F-star Therapeutics Agree to Combine to Pursue Mission of Creating Next Generation Immunotherapies
Combined company will operate as F-star Therapeutics and advance pipeline of multiple clinical-stage immuno-oncology programs Combined company expected to have at least $40 million in cash prior to closing Spring Bank stockholders to receive two separate …